QQQ   417.37 (-1.43%)
AAPL   165.02 (-1.21%)
MSFT   399.56 (-1.17%)
META   483.42 (-3.66%)
GOOGL   153.85 (-1.38%)
AMZN   174.69 (-2.53%)
TSLA   149.12 (-0.54%)
NVDA   810.20 (-4.31%)
AMD   149.38 (-3.68%)
NIO   3.84 (-4.00%)
BABA   68.76 (-0.17%)
T   16.37 (+0.24%)
F   12.10 (+0.33%)
MU   107.40 (-4.05%)
GE   148.73 (-2.75%)
CGC   8.08 (+3.19%)
DIS   112.08 (-0.31%)
AMC   3.23 (+10.62%)
PFE   25.77 (+1.50%)
PYPL   62.08 (-0.03%)
XOM   120.09 (+1.32%)
QQQ   417.37 (-1.43%)
AAPL   165.02 (-1.21%)
MSFT   399.56 (-1.17%)
META   483.42 (-3.66%)
GOOGL   153.85 (-1.38%)
AMZN   174.69 (-2.53%)
TSLA   149.12 (-0.54%)
NVDA   810.20 (-4.31%)
AMD   149.38 (-3.68%)
NIO   3.84 (-4.00%)
BABA   68.76 (-0.17%)
T   16.37 (+0.24%)
F   12.10 (+0.33%)
MU   107.40 (-4.05%)
GE   148.73 (-2.75%)
CGC   8.08 (+3.19%)
DIS   112.08 (-0.31%)
AMC   3.23 (+10.62%)
PFE   25.77 (+1.50%)
PYPL   62.08 (-0.03%)
XOM   120.09 (+1.32%)
QQQ   417.37 (-1.43%)
AAPL   165.02 (-1.21%)
MSFT   399.56 (-1.17%)
META   483.42 (-3.66%)
GOOGL   153.85 (-1.38%)
AMZN   174.69 (-2.53%)
TSLA   149.12 (-0.54%)
NVDA   810.20 (-4.31%)
AMD   149.38 (-3.68%)
NIO   3.84 (-4.00%)
BABA   68.76 (-0.17%)
T   16.37 (+0.24%)
F   12.10 (+0.33%)
MU   107.40 (-4.05%)
GE   148.73 (-2.75%)
CGC   8.08 (+3.19%)
DIS   112.08 (-0.31%)
AMC   3.23 (+10.62%)
PFE   25.77 (+1.50%)
PYPL   62.08 (-0.03%)
XOM   120.09 (+1.32%)
QQQ   417.37 (-1.43%)
AAPL   165.02 (-1.21%)
MSFT   399.56 (-1.17%)
META   483.42 (-3.66%)
GOOGL   153.85 (-1.38%)
AMZN   174.69 (-2.53%)
TSLA   149.12 (-0.54%)
NVDA   810.20 (-4.31%)
AMD   149.38 (-3.68%)
NIO   3.84 (-4.00%)
BABA   68.76 (-0.17%)
T   16.37 (+0.24%)
F   12.10 (+0.33%)
MU   107.40 (-4.05%)
GE   148.73 (-2.75%)
CGC   8.08 (+3.19%)
DIS   112.08 (-0.31%)
AMC   3.23 (+10.62%)
PFE   25.77 (+1.50%)
PYPL   62.08 (-0.03%)
XOM   120.09 (+1.32%)
LON:RLM

Realm Therapeutics (RLM) Share Price, News & Analysis

GBX 11.50
0.00 (0.00%)
(As of 03/26/2019)
Today's Range
11.50
11.50
50-Day Range
11.50
11.50
52-Week Range
5.80
40
Volume
169,853 shs
Average Volume
800,861 shs
Market Capitalization
£13.40 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

About Realm Therapeutics

Realm Therapeutics Plc, a biopharmaceutical company, focuses on developing therapies for the treatment of immune-mediated diseases in adults and children. Its product pipeline includes PRO22, a topical gel, which is conducting initial Phase II clinical studies for the treatment of atopic dermatitis. The company was formerly known as PuriCore plc and changed its name to Realm Therapeutics Plc in December 2016. Realm Therapeutics Plc was founded in 2016 and is headquartered in Malvern, Pennsylvania.

RLM Stock Price History

RLM Stock News Headlines

Defence of the Realm Act (DORA)
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
Realm Therapeutics PLC ADR (RLM_old)
See More Headlines
Receive RLM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Realm Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£501,919.00
Cash Flow
GBX 20.30 per share
Book Value
GBX 20.80 per share

Miscellaneous

Free Float
N/A
Market Cap
£13.40 million
Optionable
Not Optionable
Beta
N/A
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Mr. John Alexander Martin (Age 51)
    CEO & Exec. Director
  • Ms. Marella Thorell (Age 52)
    CFO, COO, Company Sec. & Exec. Director
  • Dr. Christian Peters (Age 57)
    Chief Medical Officer

RLM Stock Analysis - Frequently Asked Questions

How have RLM shares performed in 2024?

Realm Therapeutics' stock was trading at GBX 11.50 at the beginning of the year. Since then, RLM shares have increased by 0.0% and is now trading at GBX 11.50.
View the best growth stocks for 2024 here
.

What other stocks do shareholders of Realm Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Realm Therapeutics investors own include Allena Pharmaceuticals (ALNA), AcelRx Pharmaceuticals (ACRX), Ampliphi Biosciences (APHB), Viking Therapeutics (VKTX), Arbutus Biopharma (ABUS), Aurora Cannabis (ACBFF), Aldeyra Therapeutics (ALDX), Apellis Pharmaceuticals (APLS).

How do I buy shares of Realm Therapeutics?

Shares of RLM stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

This page (LON:RLM) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners